News

Based in San Diego of California, Pharmapace has expertise in offering biometrics services for all phases of clinical trials, regulatory submissions, and post marketing support. Pharmapace will be

Innovative oncolytic viruses resulting from this collaboration will use Transgene’s proprietary next generation viral platform Invir.IO. Under the terms of the agreement Transgene will contribute its oncolytic virus

Under the terms of the agreement, Amgen and Syapse will develop observational research analytics to assess treatment outcomes for areas of unmet need in oncology. This effort will

Trelegy Ellipta is a once-daily single inhaler triple therapy, which includes fluticasone furoate (FF), umeclidinium (UMEC) and vilanterol (VI). Fluticasone is an inhaled corticosteroid, while umeclidinium is a

The primary endpoint of the trial is progression-free survival, and the secondary endpoints are overall survival and objective response rate. “Clinical observations suggest cabozantinib promotes an immune-permissive environment,

Initially, research will focus on Diffuse Intrinsic Pontine Glioma (DIPG), a rare and highly aggressive brain stem tumor. As part of the research collaboration, Tmunity will work with

Dengvaxia is said to be the first FDA-approved vaccine to prevent dengue disease caused by all dengue virus serotypes (1, 2, 3 and 4) in people aged between

KALYDECO is already approved in the U.S., Canada and EU for the treatment of CF in patients ages 12 months and older. “Today’s approval for KALYDECO allows physicians

With over 250 employees, the San Diego research center will focus on leveraging specialized drug discovery technologies, as well as advancing discovery research in gastroenterology and neuroscience, said